Begin Phase 1b/2a trial for VIR-7832
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 28 Jan 2021
- Due
- 31 Mar 2021
- Delivered
- Q2 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“VIR-7832, which is currently planned to enter a Phase 1b/2a trial this quarter.”
What we found
Evidence strength A What the grades mean
The company stated in multiple filings that it initiated the Phase 1b/2a clinical trial for VIR-7832 in the second quarter of 2021, which is after the first quarter deadline.
-
A Vir Biotechnology, Inc. 10-Q filed 2021-08-05
“In April, the first patient was dosed in the United Kingdom National Health Service-supported AGILE initiative. The trial initiative is the first to evaluate VIR-7832 in a Phase 1b/2a trial” ✓ confirmed on the page
-
A Vir Biotechnology, Inc. 10-Q filed 2021-05-06
“in the second quarter of 2021, we initiated a Phase 1b/2a clinical trial for VIR-7832” ✓ confirmed on the page
Market reaction: the shares moved -11.3% against the S&P 500 over the three sessions around the disclosure (5 May 2021 to 10 May 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Phase 1b/2a trial for VIR-7832
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Vir Biotechnology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-VIR-022588 · Corrections policy